Dr Kevin Cox (Non Exec Chair)29 Aug 2021 17:59
..has (according to his Valirx bio) "over 25 yearsβ experience in the life science industry. Serving as CEO of high growth biotechnology businesses, he has extensive experience in strategy, corporate development, M&A, financing and joint ventures".
Now I accept some investors are unhappy with Cenkos' 6%, however it's highly unlikely Suzy will have been badly advised by her right hand man.
Personally I'm waiting to see either a deal RNS, or possibly a new strategy outlined in the Q&A, before making a judgement about my holding here.
The patents have been strengthened and I remain confident the Board will deliver.
GLA
GLA